SCHEMBL2335924

SCHEMBL2335924

Cc1cc(N)c2ccccc2[n+]1C(I)CCCCCCCCC(I)[n+]1c(C)cc(N)c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 13/20 0.55
MEN1 O00255 4/20 0.55
GMNN O75496 4/20 0.55
LMNA P02545 4/20 0.55
POLB P06746 4/20 0.55
MAPT P10636 4/20 0.55
APEX1 P27695 4/20 0.55
RECQL P46063 4/20 0.55
BLM P54132 4/20 0.55
PMP22 Q01453 4/20 0.55
KMT2A Q03164 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
NPSR1 Q6W5P4 4/20 0.55
TDP1 Q9NUW8 4/20 0.55
ALDH1A1 P00352 3/20 0.55
TP53 P04637 3/20 0.55
CYP3A4 P08684 3/20 0.55
HSD17B10 Q99714 3/20 0.55
CYP2D6 P10635 2/20 0.55
ALOX15 P16050 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL14740350 0.83 PRKCA (0.43) PRKCAMEN1GMNNLMNAPOLB
Hydrochloric Acid SCHEMBL14720060 0.80 MEN1 (0.53) PRKCAMEN1GMNNLMNAPOLB
SCHEMBL14740356 0.74 KDM4E (0.39) MEN1LMNAKMT2ASMN1; SMN2NPSR1
SCHEMBL14738733 0.72 CHKA (0.40) PRKCAMEN1GMNNLMNAPOLB
SCHEMBL2329328 0.72 CHKA (0.40) PRKCAMEN1GMNNLMNAPOLB
SCHEMBL14739219 0.72 CHKA (0.40) PRKCAMEN1GMNNLMNAPOLB
SCHEMBL6298118 0.71 PRKCA (1.00) PRKCAMEN1GMNNLMNAPOLB
SCHEMBL6299633 0.71 PRKCA (1.00) PRKCAMEN1GMNNLMNAPOLB
Dequalinium SCHEMBL29557297 0.71 PRKCA (1.00) PRKCAMEN1GMNNLMNAPOLB
Dequalinium SCHEMBL149457 0.71 PRKCA (1.00) PRKCAMEN1GMNNLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12247246-B2 Identification of inhibitors of TcpC and TIR NADase activity WASHINGTON UNIVERSITY (US) 2025-03-11 US disclosed
US-20230272449-A1 IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY WASHINGTON UNIVERSITY 2023-08-31 US disclosed
US-20200283820-A1 IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY WASHINGTON UNIVERSITY 2020-09-10 US disclosed
US-20190298841-A1 Nucleic Acid Complexes PROCARTA BIOSYSTEMS LTD (GB) 2019-10-03 US disclosed
US-10350299-B2 Nucleic acid complexes PROCARTA BIOSYSTEMS LTD. (GB) 2019-07-16 US disclosed
US-20170340745-A1 NUCLEIC ACID COMPLEXES PROCARTA BIOSYSTEMS LTD. (GB) 2017-11-30 US disclosed
US-9669101-B2 Nucleic acid complexes PROCARTA BIOSYSTEMS LTD (GB) 2017-06-06 US disclosed
US-9550991-B2 Transcription factor decoys PROCARTA BIOSYSTEMS LTD. (GB) 2017-01-24 US disclosed
EP-2552455-B1 TRANSCRIPTION FACTOR DECOYS PROCARTA BIOSYSTEMS LTD (GB) 2016-12-28 EP disclosed
US-20150196652-A1 NUCLEIC ACID COMPLEXES PROCARTA BIOSYSTEMS LTD (GB) 2015-07-16 US disclosed
US-9024005-B2 Nucleic acid complexes PROCARTA BIOSYSTEMS LTD (GB) 2015-05-05 US disclosed
US-20140274800-A1 TRANSCRIPTION FACTOR DECOYS FOR THE TREATMENT AND PREVENTION OF INFECTIONS CAUSED BY BACTERIA INCLUDING CLOSTRIDIUM DIFFICILE PROCARTA BIOSYSTEMS LTD. (GB) 2014-09-18 US disclosed
US-20130252881-A1 Transcription Factor Decoys PROCARTA BIOSYSTEMS LTD. (GB) 2013-09-26 US disclosed
US-20130059775-A1 Nucleic Acid Complexes PROCARTA BIOSYSTEMS LTD (GB) 2013-03-07 US disclosed
EP-2533815-A1 NUCLEIC ACID COMPLEXES Procarta Biosystems Ltd (GB) 2012-12-19 EP disclosed
WO-2011098829-A1 NUCLEIC ACID COMPLEXES PROCARTA BIOSYSTEMS LTD (GB) 2011-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230272449-A1 IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY NADK, NAPRT, TIPARP PRKCA 2174/4885MEN1 3678/4885GMNN 2521/4885
US-10350299-B2 Nucleic acid complexes ZFR, SUB1, RELA PRKCA 4524/4885MEN1 4030/4885GMNN 1762/4885
US-12247246-B2 Identification of inhibitors of TcpC and TIR NADase activity NADK, NAPRT, TIPARP PRKCA 2174/4885MEN1 3678/4885GMNN 2521/4885
US-20170340745-A1 NUCLEIC ACID COMPLEXES ZFR, SUB1, RELA PRKCA 4524/4885MEN1 4030/4885GMNN 1762/4885
US-20200283820-A1 IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY NADK, NAPRT, TIPARP PRKCA 2174/4885MEN1 3678/4885GMNN 2521/4885
US-20190298841-A1 Nucleic Acid Complexes ZFR, SUB1, RELA PRKCA 4524/4885MEN1 4030/4885GMNN 1762/4885
US-20150196652-A1 NUCLEIC ACID COMPLEXES ZFR, SUB1, RELA PRKCA 4524/4885MEN1 4030/4885GMNN 1762/4885
US-20130059775-A1 Nucleic Acid Complexes ZFR, SUB1, RELA PRKCA 4524/4885MEN1 4030/4885GMNN 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.